Loading stock data…
$2.11+0.02 (+0.96%)
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
Fate Therapeutics, Inc. in the Healthcare sector is trading at $2.11 with a market capitalization of $261M. Wall Street consensus targets $5.74 (9 analysts), implying a +172.2% move over the next 12 months. The stock is currently 35% below its 52-week high of $3.23, remaining 9.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.08M↑ | $1.30M↓ | $1.37M↓ | $1.74M↓ | $1.91M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$31.13M↑ | -$33.00M↑ | -$34.72M | -$34.73M↑ | -$36.97M |
| Net Income | -$30.16M↑ | -$31.21M↑ | -$32.37M↓ | -$32.25M↑ | -$34.07M |
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and ...